Pfizer’s IGF-1 Inhibitor Leads Pack In Phase III For NSCLC
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength
You may also be interested in...
Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On
News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without
Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On
News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without
Pfizer Halts Phase III Figitumumab Trial In NSCLC But Forges On With Other Studies
Insulin growth factor-1 receptor inhibitor is one of Pfizer's lead oncology candidates, but the company is not throwing in the towel on figitumumab yet.